tbuckley/cabot-search huggingface dataset:
Results of FRESH START: A randomized controlled trial to improve diet and exercise behaviors in breast and prostate cancer survivors
Authors: W. Demark-Wahnefried, E. Clipp, I. Lipkus, D. Lobach, B. Peterson, D. Snyder, R. Sloane, J. Macri, C. McBride, W. Kraus
Journal: Journal of Clinical Oncology (2006)

8503 Background: Cancer survivors are at increased risk for cardiovascular disease, diabetes, osteoporosis and other cancers. A healthy diet and regular exercise may improve the health and well-being of survivors and ultimately reduce health risks. Methods: 543 individuals within 9-mths of diagnosis with locoregional breast or prostate cancer were referred by 445 providers and recruited from 39 states and 2 provinces within North America. Subjects were randomized to an arm that received a 10-mth program of tailored mailed print materials to promote fruit and vegetable (F&amp;V) consumption, reduce total/saturated fat intake and/or increase exercise or an arm that received a 10-mth program of non-tailored mailed materials on diet and exercise available in the public domain. Telephone surveys conducted at baseline and 1-yr follow-up assessed body mass index (BMI), and responses to the Diet History Questionnaire, the 7-Day Physical Activity Recall and psychosocial/behavioral indices. Anthropometric data were obtained on a 22% subsample to validate self-reports. Results: Complete baseline and follow-up data were obtained on 519 participants (4% attrition). Sample demographics were as follows: mean age = 57 (range: 22–85), 85% white, 56% female, and 64% overweight/obese (none were underweight). Uncontrolled analyses (t-tests) indicate that both arms significantly improved their diet and exercise behaviors (p’s &lt;.05) over the 1-year study period; however significantly greater changes occurred in the experimental arm (see table). Conclusion: The FRESH START intervention was successful in changing the behaviors of individuals with newly diagnosed cancers. Serum assays and collection of 2-yr follow-up data (to determine the durability of longer term behavior change) are currently underway. Further study is needed to determine if the effects of this intervention generalize to other populations of cancer survivors (i.e., other cancers and individuals further-out from diagnosis). [Table: see text] No significant financial relationships to disclose.
Adoptive Transfer Of WT-1 Specific HLA Class 2 Restricted Donor-Derived T-cells Induces Sustained Remission Of AML Relapse Post Transplant Presenting As Leukemia Cutis
Authors: Susan E. Prockop, Ekaterina Doubrovina, Roberta Adams, Farid Boulad, Nancy A. Kernan, Richard J. O'Reilly
Journal: Blood (2013)
<i>hCNT1</i> in Waldenström’s macroglobulinemia (WM) and small lymphocytic lymphoma (SLL) patients (pts): A possible predictive biomarker of 2-chloro-2`-deoxyadenosine (2-CDA) clinical activity
Authors: C. Rabascio, L. Saronni, P. Antoniotti, V. Raia, F. Bertolini, D. Laszlo, M. Cassatella, N. Marziliano, E. Arbustini, G. Martinelli
Journal: Journal of Clinical Oncology (2006)

13087 Background: The resistance mechanism to 2-CDA is not completely known. In this study we used pharmacogenomic to identify genetic factors that influence drug response and to better investigate 2-CDA complex intracellular metabolism. Methods: Using Real-time PCR method (ABI-PRISM 7000 machine) we amplified seven genes, encoding for equilibrative and concentrative nucleoside transporter (hENT1, hCNT1), deoxycytidine and deoxyguanosine kinase (dCK, dGK), 5`-nucleotidase (5`NT), ribonucleotide reductase catalytic and regulatory (RR1, RR2) subunits, in bone marrow (BM) at baseline of 17 pts with WM or SLL in order to verify the correlation between gene expression and clinical outcome. All pts were treated with a combination therapy (2-CDA 0.1 mg/kg sc injection and Rituximab at standard schedule). Quantitation was performed using the Delta C T calculation: the value of gene expression was normalised to the calibrator (healthy tissue cells). Results: hCNT1 and 5’NT gene expression analysis has shown lower values in pts than in controls. The other markers didn’t show any significance. Two pts achieving partial remission (PR) presented 100 times lower hCNT1 levels (median 6.8*10 −4 , range 6.8–6.9*10 −4 ) than pts (n = 10) in complete remission (median 7.9*10 −2 , range 0.1–4.6*10 −1 ; p = 0.03). Conclusions: hCNT1 seems to be the most important gene involved in 2-CDA clinical activity and its expression may correlate with prognosis. Compared to controls, the low plasmatic RNA level of hCNT1 exhibited by our pts doesn’t seem to be predictive of lack of clinical activity of 2-CDA. However the lower level of hCNT1 plasmatic expression detected in the two pts who achieved only PR could suggest a possible relationship between reduced hCNT1 plasmatic expression and a diminished clinical activity of 2-CDA. Thus it might be important to explore the possibility of standardizing a quantitative method in order to identify a threshold value which could be predictive of drug resistance. No significant financial relationships to disclose.
Overall and cause specific long term mortality following childhood cancer: The role of cancer treatment
Authors: F. de Vathaire, M. Tukenova, O. Oberlin, F. Doyon, C. Guibout
Journal: Journal of Clinical Oncology (2007)

9520 Background: A multi-centre French cohort study was performed to evaluate the role of treatment in the long-term overall and cause-specific mortality among childhood cancer survivors. Methods: This study cohort included 3,057 patients treated for a solid tumours before the age of 17 between 1942–1986, in 5 French centres and who survived at least 5 years from diagnosis. Detailed clinical and therapeutic data were extracted for each patients from medical records. For 2,081of the 2,178 patients who received radiotherapy, radiation doses were estimated at 188 anatomical sites, including heart (7 sites) and lungs (10 sites). 98% of patients were identified in French National Registry of Physical Persons (RNIPP) and we obtained the death causes of 95% of dead patients. Overall and cause-specific mortality standardized ratios (SMR), absolute excess risk (AER) of death were studied using Poisson regression. Results: 50% of patients were treated by chemotherapy (CT) plus radiotherapy (RT), 22% by CT alone and 21% by RT alone. During an average follow-up of 25 years, 465 patients dead. The overall SMR was 7.3 (95% CI: 6.7–8.0) and AER was 6 deaths per 1,000 person-years. SMR for death due to cancer other than the 1st cancer (SC) was 16.1 (95%, CI 13.5–18.9). SMRs were significantly elevated for non-cancer overall mortality, infectious and parasitic diseases, diseases of the circulatory, nervous and respiratory system, congenital anomalies, symptoms, signs and ill- defined conditions’ (SMRs of 2.6, 15.7, 6.4, 8.5, 4.6, 3.2, respectively). RT was associated an increase in the risk for overall and SC related deaths (RR = 2.0; 95% CI: 1.5–2.7; RR = 1.8; 95% CI: 1.1–2.9; respectively). CT was associated with an increased risk for overall, SC and non- cancer related deaths (RR = 1.6; 95% CI: 1.3–2.0; RR = 1.9; 95% CI: 1.2–3.0; RR = 1.8; 95% CI: 1.1–2.9 respectively). We were not able to find any evidence for an interaction between CT and RT, whatever the end point considered. Among the 26 circulatory deaths, 24 received RT, the mean radiation dose of the heart (P=0.0006) and treatment with spindle inhibitors (P=0.009) were significantly associated to death by cardiac disease. Conclusions: In the future, death due to cardiac pathologies could be an important issue for long term survivors of childhood cancer. No significant financial relationships to disclose.
Successful Treatment of Metastatic Renal Cell Carcinoma With a Nonmyeloablative Allogeneic Peripheral-Blood Progenitor-Cell Transplant: Evidence for a Graft-Versus-Tumor Effect
Authors: Richard W. Childs, Emmanuel Clave, John Tisdale, Michelle Plante, Nancy Hensel, John Barrett
Journal: Journal of Clinical Oncology (1999)

PURPOSE: A 50-year-old man developed progressive pulmonary metastasis resistant to interferon alfa-2b treatment 7 months after he underwent left nephrectomy for stage III renal cell carcinoma. We performed a nonmyeloablative allogeneic peripheral-blood stem-cell transplant in this patient to exploit a possible graft-versus-tumor effect from allogeneic lymphocytes. MATERIALS AND METHODS: The conditioning regimen consisted of fludarabine and cyclophosphamide followed by a T-cell replete, granulocyte-colony stimulating-factor–mobilized peripheral-blood stem-cell transplant from his HLA-identical brother. Cyclosporine was administered from days –4 to +45 to prevent graft rejection and acute graft-versus-host disease (GVHD). RESULTS: Serial polymerase chain reaction analysis of hematopoietic lineage-specific minisatellites initiallyshowed mixed chimerism in CD14 + and CD15 + myeloid cells, CD3 + T cells, and CD34 + progenitor cells, with rapid conversion to 100% donor T-cell chimerism by day +60 and 100% donor myeloid cells by day +100. Serial computed tomography scans of the chest showed stable disease at day +30, slight regression of pulmonary lesions at day +63, and complete disappearance of all pulmonary metastatic disease by day +110. Mild transient acute GVHD disease of the skin occurred on day +60 and limited chronic GVHD of the skin occurred by day +200. CONCLUSION: The complete regression of metastatic disease, which has now been maintained for more than 1 year, is compatible with a graft-versus-tumor effect.
Relation between carcinoembryonic antigen (CEA) production in colorectal cancer (CRC) tissue and serum CEA levels: Comparison between the time of recurrence and initial diagnosis.
Authors: Gota Saito, Sotaro Sadahiro, Kazutake Okada, Akira Tanaka, Toshiyuki Suzuki, Akemi Kamijo
Journal: Journal of Clinical Oncology (2015)

561 Background: Because serum CEA often becomes positive before the diagnosis of recurrence, CEA is widely used for postoperative surveillance. Serum CEA is negative at initial diagnosis as well as at recurrence in some patients. We examined the relation between serum CEA levels and tissue CEA staining status both at initial surgery and at recurrence. Methods: Between 1998 to 2012, 1,306 patients (pts) with colon cancer (CC) underwent curative resection. Serum CEA levels were measured at initial surgery and at recurrence and immunohistochemical staining for CEA in primary and metastatic lesions was performed in 46 pts. Serum CEA levels of 10ng/mL or more were regarded as positive. Results: Serum CEA were positive in 17 pts (37%) at initial surgery and in 20 (43%) at recurrence. CEA staining was positive in primary lesions in 24 pts (52%) and metastatic lesions in 33 (72%). The positive rate was higher in metastatic lesions (p=0.053). Among pts in whom serum CEA was positive at initial surgery, CEA staining in primary lesion was positive in 12 pts (71%) and negative in 5 (29%). Among pts in whom serum CEA was negative, CEA staining in primary lesion was positive in 12 pts (41%) and negative in 17 (59%). Serum CEA at initial surgery was not related to CEA staining in primary lesion(p=0.0722). Among pts positive for serum CEA at recurrence, CEA staining in metastatic lesions was positive in 19 pts(95%) and negative in 1(5%). Among pts negative for CEA at recurrence, CEA staining in metastatic lesions was positive in 14 pts (54%) and negative in 12 (46%). Serum CEA at recurrence was significantly related to CEA staining in metastatic lesions (p=0.0026). Among 33 pts in whom CEA staining was positive at recurrence, serum CEA was negative in 14 (42%). Conclusions: In pts with recurrence of CC, there was no relation between the staining CEA status and serum CEA level at initial diagnosis. In contrast, these variables were significantly related at recurrence. However, 42% of pts with positive staining for CEA in metastatic lesions had negative serum CEA levels. Our findings suggest that factors besides the production of CEA by cancer cells are related to serum CEA levels.
Assessment of intra and interfractional organ motion during adjuvant radiochemotherapy in gastric cancer
Authors: B. A. Wysocka, Z. Kassam, G. Lockwood, J. Brierley, L. Dawson, J. Ringash
Journal: Journal of Clinical Oncology (2007)

15132 Background: Adjuvant combined chemotherapy and radiotherapy (RT) in gastric cancer improves survival, however acute toxicity is substantial. Toxicity may be improved with three-dimensional (3D) RT, but organ motion must be considered in planning target volume (PTV) delineation. Methods: Participants (n=22) had baseline free breathing planning CT (CT0) with BodyFix immobilization. Abdominal CTs in free breathing (FB), inhale (I) and exhale (E) states were obtained in weeks 1, 3 and 5 of RT. Datasets were fused to CT0 in Pinnacle 3 6.2 planning system using bone registration. Volumes of interest (VOIs) [right (R) and left (L) kidney, liver, stomach, pancreas, celiac axis and porta hepatis] were contoured and points of interest (POIs) were placed at each centre of mass. POIs were manually placed at the left dome of diaphragm and splenic hilum. Organ motion was determined by the difference between POI positions in cranial-caudal (CC), anterior-posterior (AP) and right-left (RL) directions. Maximal respiratory motion was determined from the difference between I and E positions. Interfractional displacement in organs relative to bones at weeks 1, 3 and 5 was determined on FB scans as compared to baseline. Results: Interfractional organ motion was maximal in CC direction with median absolute displacements (range) in mm of: splenic hilum 10 (0–52), stomach 8 (0.4–27.2), liver 7.4 (0.5–23.6), diaphragm 6 (0–28), L kidney 5.7 (0–37.3), R kidney 5.3 (0.2–35.3), pancreas 5.7 (0.3–29.1), porta hepatis 4 (0–14) and celiac axis 1.7 (0–9.1). Median interfraction displacement (range) in CC, AP and RL in mm for all organs was: 5.7 (0- 52), 2.1 (0–23.1), 2.3 (0–15.9). Positional difference between I and E state (median for all organs) was: 16 mm CC, 5.9 mm AP, and 1.7 mm RL with maximal individual breathing excursions of 59.9, 30.2 and 21.1 mm, respectively. Conclusions: Interfraction organ displacement relative to bones can be quantified and used in the safe design of 3D conformal radiotherapy. Respiratory motion can be substantial in some individuals. Accounting for organ motion in 3D RT planning is necessary and may reduce the toxicity of treatment. No significant financial relationships to disclose.
Lymphoplasmacytic Cells and Mast Cells Are Targets for Imatinib Mesylate (Gleevec, Glivec) in Waldenstrom’s Macroglobulinemia.
Authors: Olivier Tournilhac, Daniel Ditzel Santos, Lian Xu, Evdoxia Hatjiharissi, Yu Tsu, Laurie Catley, Zachary Hunter, Andrew Branagan, Renate Burger, Reshma Shringarpure, Joshua Boyce, Kenneth C. Anderson, Steven P. Treon
Journal: Blood (2004)
Silencing pathways that underlie platinum resistance in ovarian cancer cells using small interfering RNA
Authors: A. Elahi, M. A. Martino, J. Cragun, M. I. Goldberg, M. S. Hoffman, S. Tebes, C. Klippel, P. Kruk, R. Sutphen, J. Lancaster
Journal: Journal of Clinical Oncology (2005)

5117 Background: Primary therapy for women with advanced stage epithelial ovarian cancer includes primary surgical cytoreduction followed by platinum-based chemotherapy. Although nearly 70% of patients demonstrate a complete clinical response to primary therapy, the majority of patients will develop platinum-resistant recurrent disease. Our understanding of this chemo-resistance remains incomplete. The expression of genes such as c-myc have been shown to be associated with chemoresistance in several human cancers. Recently, using microarray expression analysis of 55 primary epithelial ovarian cancers, we demonstrated that members of the c-myc pathway are predictive of response to primary platinum therapy. We hypothesized that increased c-myc gene expression also underlies platinum resistance in ovarian cancer cell lines, and that it can be reduced by use of a c-myc-targeted small interfering RNA (si-cmyc) approach, thus reversing platinum resistance. Methods: Expression of the c-myc gene was measured in platinum-sensitive (OV2008) mother and platinum-resistant (C13) daughter ovarian cancer cell lines using quantitative real time polymerase chain reaction (QRTPCR). Platinum-resistant cells were then subject to c-myc-targeted small interfering RNA (50nM, 100nM and 150nM), and c-myc gene expression was evaluated using Western blot analysis. Platinum-resistant ovarian cancer cells, subject to successful c-myc expression silencing by siRNA, were then evaluated for platinum-response using the MMT assay. Results: Expression of the c-myc gene was 1.78-fold higher in platinum-resistant versus platinum-sensitive ovarian cancer cells. Western blot analysis demonstrated a reduction of c-myc gene expression by 95% in platinum-resistant ovarian cancer cells subject to c-myc-targeted siRNA at 150nM. Conclusions: These findings support the hypothesis that the c-myc gene pathway is an important determinant of platinum-response in ovarian cancer cells. Further, we have demonstrated that siRNA approaches can selectively silence genes that underlie platinum-response and may thus represent a novel targeted molecular therapeutic approach to patients with platinum-resistant ovarian cancer. No significant financial relationships to disclose.
Long-term benefit from trabectedin (T) in myxoid liposarcoma (MLS) patients
Authors: F. Grosso, R. G. Sanfilippo, P. Dileo, C. Morosi, E. Virdis, A. Gronchi, J. Jimeno, S. Pilotti, M. D’Incalci, P. G. Casali
Journal: Journal of Clinical Oncology (2008)

10582 Background: To assess long-term follow-up data on efficacy of T in MLS. Methods: Since September 2002, 32 patients (pts) with locally advanced/metastatic pretreated MLS received T within an expanded access programme at our institute. Diagnosis were centrally reviewed and confirmed by citogenetics when feasible. Data are now updated focusing on long term follow-up. Results: Median age at T start was 51 (range 32–73). T was given as a 24-hr continuous infusion every 21 days, at dose levels from 1.0 to 1.5 mg/sqm. A total of 338 courses, and a median of 10 courses per patient (IQ 6–15), were delivered. Response rate according to RECIST was 51%. Median PFS was 17 months, and median overall survival was 30 months. Ten patients stopped treatment after a median of 9 courses (IQ range 7–13), in the absence of visible residual disease: 7 pts underwent complete surgery of residual locally advanced/metastatic disease having obtained response or prolonged tumor control, 1 patient received radiotherapy on residual disease, 2 patients reached a complete response with chemotherapy. In this subgroup, at a median follow up of 22 months (IQ 18–26, range 11–36) from treatment start, and 11 months (IQ 11–18, range 5–20) from treatment end, only one patients (having reached CR with T) relapsed (after 19 months from stopping T). Conclusions: MLS show a high response rate to T. At a long follow-up, responses to T appear to translate into prolonged PFS. Surgery of residual disease was feasible and extensively used in this group and may have contributed to maximize the benefit from T in a subset of these patients. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration PharmaMar Zeltia PharmaMar Jansen Cilag, PharmaMar PharmaMar
Influence of vascular comorbities and race on erectile dysfunction after prostate cancer radiotherapy.
Authors: Yuefeng Wang, Tian Liu, Peter J. Rossi, Sherrie Cooper, Ashesh B. Jani
Journal: Journal of Clinical Oncology (2012)

29 Background: Vascular comorbidities (VC’s) [hypertension (HTN), diabetes (DM) and/or hyperlipidemia (HL)] are known factors related to erectile dysfunction (ED) prior to radiotherapy (XRT). We have undertaken this study to understand the influence of VC’s on post-XRT ED incidence, and to further characterize ED incidence by racial groups. Methods: We reviewed the charts of 732 prostate cancer patients [267 white (W) and 465 African American (AA)] who received XRT [external beam radiotherapy (EBRT) and/or brachytherapy (BT)] with or without use of hormone therapy between 1999 and 2010. The number of pre-XRT VC’s (0, 1, 2, or 3) was determined by medical history and medication list. ED (defined by use of erectile aids or by documentation of moderate or high sexual dysfunction on patient history) was determined pre-XRT as well as 1, 6, and 12 months post-XRT and compared by follow-up interval since XRT, by number of VC’s, and by race in each case using the two sample proportion test. Results: ED incidence progressively increased with time from 22% pre-XRT to 52% 12 months post-XRT (p&lt;0.001). Additionally, ED incidence increased with increasing of number of VC’s – 12-month incidences between patients with 0 vs 2 (p=0.024), 0 vs 3 (p&lt;0.001), 1 vs 3 (p&lt;0.001), and 2 vs 3 (p=0.004) VC’s were statistically significant (0 vs 1 and 1 vs 2 were non-significant). Pre-XRT ED incidence was 20% vs 23% (for W vs AA patients, p=0.156) due to higher incidence of VC’s in the AA group. At 12 month follow-up, ED incidences for W vs AA patients were 38% vs 45%, 46% vs 49%, 52% vs 57%, and 71% vs 75% with 0, 1, 2 and 3 co-morbidities, respectively (all p-values non-significant). Conclusions: Our analysis represents the first effort exploring post-XRT ED as determined by the number VC’s and by race. Our results suggest that number of VC’s have a significant effect on development of post-XRT ED. Pre- and post-XRT ED appear to be independent of race when number of VC’s are considered. Our results can be used to guide physicians in counseling patients on the incidence of ED by number of VC’s and as preliminary data for prospective efforts aimed at reducing post-XRT ED.
Long-term outcome results of the phase III PROMISE-GIM6 study evaluating the role of LHRH analog (LHRHa) during chemotherapy as a strategy to reduce ovarian failure in early breast cancer patients
Authors: M. Lambertini, L. Boni, A. Michelotti, T. Gamucci, T. Scotto, S. Gori, M. Giordano, O. Garrone, A. Levaggi, F. Poggio, S. Giraudi, C. Bighin, C. Vecchio, M.R. Sertoli, S. Pastorino, P. Pronzato, L. Del Mastro
Journal: Annals of Oncology (2015)
A Chromosome 14q11/TCRα/δ Specific Yeast Artificial Chromosome Improves the Detection Rate and Characterization of Chromosome Abnormalities in T-Lymphoproliferative Disorders
Authors: K.A. Rack, F. Cornélis, I. Radford-Weiss, A. Bernheim, C.J. Harrison, O. Hermine, M. Prieur, M. Vekemans, E.A. Macintyre
Journal: Blood (1997)